美股异动丨Viking Therapeutics大涨超15%，计划推进口服减肥药后期测试

Core Viewpoint - Viking Therapeutics (VKTX.US) shares surged over 15%, reaching $32.9, following the announcement of advancing its experimental weight loss drug VK2735 into late-stage research in Q3 of this year [1] Group 1 - The company plans to move VK2735, a weight loss pill, into late-stage research [1] - Mid-stage research indicates that a low-dose oral treatment strategy can effectively maintain weight [1]